MSN MoneyCentral - CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. ISIS today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a ...